WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient ...
– Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – – Joined the Subcutaneous Drug ...
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (CMRA) (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient ...
Biologic medicines company Comera Life Sciences entered into a purchase agreement with Arena Business Solutions Global worth up to $15 million. The agreement has a provision to increase by another $15 ...
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and ...
WOBURN, Mass. & MIAMI--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and ...
OTR is a $107 million SPAC led by veteran investor and entrepreneur Nicholas J. Singer, who serves as Chairman and Chief Executive Officer. The team is comprised of growth-oriented executives with a ...
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve ...
– Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – WOBURN, Mass., Nov. 10, 2022 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results